Lumosity

Lumosity operates at the intersection of consumer brain-training apps, cognitive research tools, and digital therapeutics. Its brain-training program covers multiple skill areas through adaptive games and performance tracking; the Human Cognition Project provides qualified researchers with cognitive tasks and research tools. The FDA clearance of LumosityRx for adults with ADHD adds a clinical dimension that is not equivalent to a general wellness app and brings different regulatory and evidence expectations. The company also has adjacent consumer products, including mindfulness and creativity apps, extending its offering beyond cognitive games. The available similarity entries repeat Lumosity itself rather than identifying distinct peers, so they do not support a precise comparative ranking. Its competitive position is therefore best understood by product scope: a long-running consumer brand with research capabilities and a newer digital-medicine direction, competing for consumer engagement while entering a more evidence-sensitive therapeutic market.

Lumosity’s funding history indicates substantial early capital formation followed by a long period without a recorded new funding round. It raised a $400,000 angel round in June 2007, $3.1 million in Series A in June 2008, $32.5 million in Series C in June 2011, and $31.5 million in Series D in August 2012. A secondary-market transaction followed on June 13, 2014; total funding is $67.5 million across five rounds. The most important strategic inflection visible in the more recent record is the FDA clearance of LumosityRx, announced December 10, 2025, for adults with ADHD. That milestone extends the business from consumer brain training toward prescription digital therapeutics, a category with distinct clinical and regulatory requirements. Its employee range is listed as 51–100, with no comparable historical headcount series to establish hiring growth. The evidence points to a mature consumer product base and a newer clinical expansion, rather than a clearly measurable recent acceleration in funding or staffing.